MCID: PMP014
MIFTS: 50

Pemphigoid

Categories: Immune diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pemphigoid

Summaries for Pemphigoid

Disease Ontology: 11 An autoimmune disease of skin and connective tissue that is characterized by subepidermal blistering especially in the lower abdomen, groin, and flexor surfaces of the extremities, creating tense blisters that do not break easily.

MalaCards based summary: Pemphigoid is related to ocular cicatricial pemphigoid and cicatricial pemphigoid. An important gene associated with Pemphigoid is DST (Dystonin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hydrocortisone succinate and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, salivary gland and bone, and related phenotypes are growth/size/body region and immune system

Wikipedia: 75 Pemphigoid is a group of rare autoimmune blistering diseases of the skin, and mucous membranes. As its... more...

Related Diseases for Pemphigoid

Diseases related to Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 936)
# Related Disease Score Top Affiliating Genes
1 ocular cicatricial pemphigoid 33.1 ITGB4 ITGA6
2 cicatricial pemphigoid 32.6 LAMA3 ITGB4 ITGA6 HLA-DQB1 DST DSG3
3 epidermolysis bullosa acquisita 32.3 LAMA3 ITGB4 DST COL17A1
4 pemphigoid gestationis 31.6 RNASE3 PPL EVPL DST DSG3 DSG1
5 gingivitis 31.1 TNF IL4 CXCL8
6 psoriasis 31.0 TNF IL5 IL4 IL17A IL13 CXCL8
7 exanthem 30.9 TNF IL4 IL17A CXCL8
8 dermatitis herpetiformis 30.9 TNF IL5 IL4 IL17A HLA-DQB1 CXCL8
9 hypereosinophilic syndrome 30.9 RNASE3 IL5 IL4 IL13 CXCL8 CCL11
10 epidermolysis bullosa, junctional 1a, intermediate 30.9 LAMA3 ITGB4 COL17A1
11 epidermolysis bullosa, junctional 4, intermediate 30.9 DST COL17A1
12 intermediate generalized junctional epidermolysis bullosa 30.8 LAMA3 ITGB4 COL17A1
13 scabies 30.8 IL5 IL4 IL13 DST COL17A1
14 conjunctivitis 30.7 TNF RNASE3 IL5 IL4 IL13 CXCL8
15 autoimmune disease 30.7 TNF IL5 IL4 IL17A IL13 HLA-DQB1
16 pseudomembranous conjunctivitis 30.6 PPL EVPL DST DSG3 DSG1 COL17A1
17 pompholyx 30.6 DST COL17A1
18 blepharoconjunctivitis 30.5 IL4 IL13
19 epidermolysis bullosa 30.5 PLEC LAMA3 ITGB4 ITGA6 DST DSP
20 stomatitis 30.5 TNF IL4 CXCL8
21 pemphigus erythematosus 30.5 DSP DSG3
22 tetanus 30.5 TNF IL5 IL4 IL13
23 lichen planus 30.5 TNF IL4 IL17A DST DSG3 DSG1
24 alopecia 30.5 TNF IL4 IL17A DSP COL17A1
25 urticaria 30.5 TNF RNASE3 IL5 IL4 IL17A IL13
26 dry eye syndrome 30.5 TNF IL17A CXCL8
27 erythema multiforme 30.5 TNF IL5 IL4 IL13 DSP CXCL8
28 thyroiditis 30.5 TNF IL4 HLA-DQB1
29 localized scleroderma 30.5 TNF IL4 IL17A IL13
30 ulcerative colitis 30.4 TNF IL5 IL4 IL17A IL13 CXCL8
31 dermatitis 30.4 TNF RNASE3 IL5 IL4 IL17A IL13
32 pemphigus 30.4 TNF PPL IL4 IL17A HLA-DQB1 EVPL
33 basal cell carcinoma 30.4 TNF ITGB4 ITGA6 DST COL17A1
34 purpura 30.4 TNF IL4 IL17A CXCL8
35 systemic scleroderma 30.4 TNF IL4 IL17A IL13 CXCL8
36 chronic urticaria 30.3 RNASE3 IL5 HLA-DQB1
37 colitis 30.3 TNF IL5 IL4 IL17A IL13 CXCL8
38 diphtheria 30.3 TNF IL5 IL4 IL13
39 chickenpox 30.3 TNF IL4 IL17A
40 periodontitis 30.3 TNF IL4 IL17A CXCL8
41 junctional epidermolysis bullosa non-herlitz type 30.3 PLEC LAMA3 ITGB4 DST COL17A1
42 rosacea 30.3 TNF IL17A CXCL8
43 haemophilus influenzae 30.3 TNF CXCL8
44 herpetiform pemphigus 30.3 DSG3 DSG1
45 severe acute respiratory syndrome 30.3 TNF IL4 CXCL8
46 dermatitis, atopic 30.2 TNF RNASE3 IL5 IL4 IL17A IL13
47 keratoconjunctivitis 30.2 TNF RNASE3 IL5 IL4 IL13 CCL11
48 primary biliary cholangitis 30.2 TNF IL4 IL17A CXCL8
49 cellulitis 30.2 TNF RNASE3 IL5 IL17A CXCL8
50 fungal infectious disease 30.2 TNF IL5 IL4 IL17A IL13 CXCL8

Graphical network of the top 20 diseases related to Pemphigoid:



Diseases related to Pemphigoid

Symptoms & Phenotypes for Pemphigoid

GenomeRNAi Phenotypes related to Pemphigoid according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 CCL11 COL17A1 CXCL8 DSG1 DSG3 DSP
2 no effect GR00402-S-2 10.14 CCL11 COL17A1 DSG1 DSG3 DST IL13

MGI Mouse Phenotypes related to Pemphigoid:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 COL17A1 DSG3 DSP DST HLA-DQB1 IL13
2 immune system MP:0005387 10.16 CCL11 COL17A1 DSG3 DSP DST HLA-DQB1
3 digestive/alimentary MP:0005381 10.15 DSG3 DSP DST HLA-DQB1 IL13 IL17A
4 renal/urinary system MP:0005367 10.03 COL17A1 DST HLA-DQB1 IL17A IL4 ITGA6
5 craniofacial MP:0005382 9.97 DSG3 DSP DST IL17A IL4 ITGA6
6 respiratory system MP:0005388 9.9 CCL11 DSG3 HLA-DQB1 IL13 IL17A IL4
7 hematopoietic system MP:0005397 9.8 CCL11 COL17A1 DSG1 DSG3 DST HLA-DQB1
8 integument MP:0010771 9.5 COL17A1 DSG1 DSG3 DSP DST EVPL

Drugs & Therapeutics for Pemphigoid

Drugs for Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
4
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
5
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
6 Hormones Phase 4
7 Hormone Antagonists Phase 4
8 glucocorticoids Phase 4
9 Vitamins Phase 4
10 Calciferol Phase 4
11 Calcium, Dietary Phase 4
12 Hydrocortisone 17-butyrate 21-propionate Phase 4
13 Immunoglobulins, Intravenous Phase 4
14 Immunoglobulin E Phase 4
15
Calcium Nutraceutical Phase 4 7440-70-2 271
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
17
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
18
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
19
Benralizumab Approved, Investigational Phase 3 1044511-01-4
20
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
21
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
22
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 4894 5755
23
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
24
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5 1875
25
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
26
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 4159 6741
27
Mycophenolic acid Approved, Investigational Phase 2, Phase 3 24280-93-1 446541
28
Dapsone Approved, Investigational Phase 2, Phase 3 80-08-0 2955
29
Rituximab Approved Phase 3 174722-31-7
30
Omalizumab Approved, Investigational Phase 3 242138-07-4
31
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
32
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
34
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
35
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7 4897
36
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
37 Immunoglobulins Phase 3
38 Antibodies Phase 3
39 Antimetabolites Phase 3
40 gamma-Globulins Phase 3
41 Rho(D) Immune Globulin Phase 3
42 Alkylating Agents Phase 3
43 Antineoplastic Agents, Alkylating Phase 3
44 Antineoplastic Agents, Hormonal Phase 2, Phase 3
45 Gentamicins Phase 3
46 Olive Phase 3
47 Immunosuppressive Agents Phase 2, Phase 3
48 Folic Acid Antagonists Phase 2, Phase 3
49 Folate Phase 2, Phase 3
50 Anti-Bacterial Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Unknown status NCT03926377 Phase 4
2 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid Unknown status NCT02360202 Phase 4 Clobetasol Propionate cream treatment
3 An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
4 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Completed NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
5 Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid. Completed NCT00525616 Phase 3 Mabthera
6 Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid Completed NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
7 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III) Completed NCT01408550 Phase 3 NPB-01;Placebo
8 Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
9 Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Compared to Conventional Topical Treatment Recruiting NCT05594472 Phase 3 Ozonated olive oil;Topical garamycin cream
10 A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD) Recruiting NCT04612790 Phase 3
11 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Recruiting NCT04206553 Phase 2, Phase 3 dupilumab;Matching Placebo;Oral corticosteroids (OCS)
12 A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid Recruiting NCT05267600 Phase 2, Phase 3 Prednisone
13 Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone Active, not recruiting NCT04744623 Phase 2, Phase 3 large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
14 An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid Not yet recruiting NCT04128176 Phase 3 Rituximab combined with Omalizumab
15 A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) Withdrawn NCT05061771 Phase 3 nomacopan (rVA576)
16 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study Unknown status NCT00802243 Phase 2 leflunomide
17 Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
18 Ixekizumab in the Treatment of Bullous Pemphigoid Completed NCT03099538 Phase 2 Ixekizumab
19 Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
20 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
21 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(PhaseⅡ). Completed NCT00809822 Phase 2 NPB-01;Placebo
22 A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
23 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
24 A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects Completed NCT04035733 Phase 2 rVA576
25 Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid Completed NCT04499235 Phase 2 Mometasone furoate;AKST4290;Placebo
26 An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid Completed NCT02226146 Phase 2
27 Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid Recruiting NCT05263505 Phase 2 Baricitinib 2 MG [Olumiant];Methotrexate;Azathioprine;Mycophenolate
28 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases Recruiting NCT04540133 Phase 2 dexamethasone 0.5mg/5ml solution;dexamethasone 0.5mg/5ml solution in Mucolox™
29 Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement. Recruiting NCT05520086 Phase 1, Phase 2 Single Dose;Double Dose
30 Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Recruiting NCT04563923 Phase 2 Avdoralimab (IPH5401)
31 Efficacy and Safety of Ustekinumab in Bullous Pemphigoid Recruiting NCT04117932 Phase 2 Ustekinumab
32 A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
33 A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid Terminated NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
34 A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid. Terminated NCT01571895 Phase 2 DF2156A
35 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
36 The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
37 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. Completed NCT02502903 Phase 1 BIV009
38 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Unknown status NCT03839069
39 Study of the Periodontal Microbiota in Gingival Cicatricial Pemphigoid Patients. Bicentric Pilot Study on 30 Patients. Unknown status NCT04555681
40 Clinical, Biological and Histological Characteristics of Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy: A National Retrospective Cohort Study Unknown status NCT04641884
41 Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland Unknown status NCT03636763 data report
42 The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors: Α Ten-year Prospective Observational Study. Unknown status NCT04469582
43 An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid Unknown status NCT02365675
44 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
45 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Unknown status NCT02874079
46 Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid Unknown status NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
47 Evaluation of Cytokines and Immunoglobulins in Serum and Blister Fluids Appeared Before Treatment and Subsequently Under Treatment in Bullous Pemphigoid Completed NCT03856840
48 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Completed NCT03272958
49 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
50 Pruritus and Pemphigoid in Nursing Home Patients Completed NCT02823067

Search NIH Clinical Center for Pemphigoid

Genetic Tests for Pemphigoid

Anatomical Context for Pemphigoid

Organs/tissues related to Pemphigoid:

MalaCards : Skin, Salivary Gland, Bone, T Cells, Eye, Neutrophil, B Cells

Publications for Pemphigoid

Articles related to Pemphigoid:

(show top 50) (show all 7526)
# Title Authors PMID Year
1
Delayed perforation after cold snare polypectomy for small colonic polyps in a patient receiving oral corticosteroids. 62
35898834 2023
2
Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study. 62
36387063 2023
3
Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review. 62
36089938 2022
4
[Eosinophilic dermatoses]. 62
36380139 2022
5
Thromboembolism and bleeding in patients with autoimmune blistering disease. 62
35962607 2022
6
Elevated serum BAFF in patients with ocular cicatricial pemphigoid. 62
36463967 2022
7
A patient with bullous pemphigoid presenting with haemorrhagic oral erosions, oral haematoma and haemoptysis. 62
36163633 2022
8
Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes. 62
31931083 2022
9
Comment on "Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes". 62
32413449 2022
10
Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study. 62
35857348 2022
11
Reply to: "Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'". 62
32417422 2022
12
Ultra-high frequency ultrasound detection of the dermo-epidermal junction: Its potential role in dermatology. 62
36017602 2022
13
Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review. 62
36311913 2022
14
Methotrexate for oral mucous membrane (cicatricial) pemphigoid: experience at an academic dermatology outpatient clinic. 62
35948167 2022
15
A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. 62
35940366 2022
16
Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid. 62
36180998 2022
17
Anti-BP180, pruritus, and thymus and activation-regulated chemokines as surrogate markers for disease activity in bullous pemphigoid. 62
35857404 2022
18
Therapeutic plasma exchange as adjunct therapy for bullous pemphigoid. 62
36148920 2022
19
Immune checkpoint inhibitor-induced bullous pemphigoid quandaries. 62
36252688 2022
20
Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma. 62
36475303 2022
21
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study. 62
35976170 2022
22
Bullous Pemphygoid and Novel Therapeutic Approaches. 62
36359364 2022
23
Comments on "Bullous pemphigoid: Three main clusters defining 3 outcome profiles". 62
35780940 2022
24
Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. 62
35796163 2022
25
What's new in the pathogeneses and triggering factors of bullous pemphigoid. 62
36412277 2022
26
Genetic susceptibility of dipeptidyl Peptidase-4 inhibitor associated bullous pemphigoid in Chinese patients with type 2 diabetes. 62
36394174 2022
27
Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center. 62
36328578 2022
28
A severe case of IgA bullous pemphigoid successfully treated with dupilumab. 62
36181411 2022
29
Hypoxia in A Patient with Anti-p200 Pemphigoid under Combined Dapsone and Pantoprazole Treatment. 62
36359356 2022
30
Pemphigoid of the pulmonary system (POPS): A review of a less recognized feature. 62
35981700 2022
31
Recalcitrant infantile bullous pemphigoid successfully treated with cyclosporine. 62
36262358 2022
32
S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. 62
36354061 2022
33
Anti-desmoglein Autoantibody in a Patient with Bullous Pemphigoid - A Case Report. 62
36386739 2022
34
Bronchial involvement in mucous membrane pemphigoid: 2 cases and a literature review. 62
36435654 2022
35
Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient. 62
36275873 2022
36
Prevalence and management of chronic hepatitis B in pemphigus and pemphigoid patients: New evidence for the safety of rituximab. 62
36001617 2022
37
Intravenous immunoglobulins in infantile dyshidrosiform bullous pemphigoid refractory to steroids and dapsone. 62
36101007 2022
38
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. 62
36358869 2022
39
Case of bullous pemphigoid refractory to corticosteroids by antiepileptic drug-induced CYP3A4. 62
36317542 2022
40
Evaluation of the Role of BIOCHIP Mosaic Based Indirect Immunofluorescence and ELISA BP 180 and BP 230 Autoantibodies in the Diagnosis of Bullous Pemphigoid Patients. 62
36386758 2022
41
Dupilumab as a novel therapy for bullous pemphigoid. 62
36440691 2022
42
A Generalized Form of Lichen Planus Pemphigoid Induced by an Oral Antidiabetic. 62
36475211 2022
43
Anti-BP230 Only Bullous Pemphigoid Constitutes a Distinct Disease Subgroup with Characteristic Serological and Clinical Features. 62
35671826 2022
44
The utility of the pattern-based approach using BIOCHIP-indirect immunofluorescence in the evaluation of subepidermal bullous disorders. 62
36444506 2022
45
Effective treatment of refractory lichen planus pemphigoides with a Janus kinase-1/2 inhibitor. 62
35980165 2022
46
Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes. 62
34089377 2022
47
Brunsting-Perry pemphigoid: a systematic review. 62
35049061 2022
48
Incidence of bullous pemphigoid and risk of mortality in the dialysis population: A retrospective cohort study. 62
35131403 2022
49
Radiation-Induced Laryngeal Mucous Membrane Pemphigoid. 62
36433793 2022
50
Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS. 62
34152480 2022

Variations for Pemphigoid

Expression for Pemphigoid

Search GEO for disease gene expression data for Pemphigoid.

Pathways for Pemphigoid

Pathways related to Pemphigoid according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CCL11 COL17A1 CXCL8 DSG1 DSP HLA-DQB1
2
Show member pathways
13.71 TNF LAMA3 ITGB4 ITGA6 IL5 IL4
3
Show member pathways
13.51 TNF ITGB4 ITGA6 IL5 IL4 IL17A
4
Show member pathways
13.36 CCL11 CXCL8 IL13 IL17A IL4 IL5
5
Show member pathways
13.28 TNF IL5 IL4 IL17A IL13 CXCL8
6
Show member pathways
13.28 CCL11 CXCL8 HLA-DQB1 IL13 IL17A IL4
7
Show member pathways
12.79 PLEC LAMA3 ITGB4 ITGA6 DST COL17A1
8
Show member pathways
12.71 PLEC LAMA3 ITGB4 ITGA6 DST COL17A1
9
Show member pathways
12.67 PLEC LAMA3 ITGB4 ITGA6 DST COL17A1
10
Show member pathways
12.63 TNF IL5 IL4 IL17A IL13 CXCL8
11
Show member pathways
12.59 PPL EVPL DSP DSG3 DSG1
12
Show member pathways
12.53 PPL PLEC EVPL DST DSP
13
Show member pathways
12.37 TNF IL4 CXCL8 CCL11
14
Show member pathways
12.14 IL17A IL4 IL5 TNF
15
Show member pathways
12.03 PLEC DSP DSG3 DSG1
16 12.02 DSP ITGA6 ITGB4 PLEC
17 11.88 TNF IL4 IL17A IL13 CXCL8 CCL11
18 11.77 CXCL8 HLA-DQB1 IL13 IL17A IL4 IL5
19 11.75 IL5 IL4 IL13 CXCL8
20 11.71 TNF IL5 IL4 IL17A IL13
21 11.69 IL5 IL4 CXCL8
22
Show member pathways
11.67 TNF IL5 IL4 CXCL8
23 11.62 IL5 IL4 CCL11
24
Show member pathways
11.6 TNF IL5 IL4 IL13
25 11.57 ITGB4 EVPL DST
26 11.46 IL5 IL4 IL13 CCL11
27 11.36 LAMA3 ITGB4 CXCL8
28 11.35 LAMA3 ITGB4 ITGA6 COL17A1
29 11.24 TNF IL17A CXCL8
30 11.22 TNF IL5 IL4 IL17A IL13
31 11.2 IL5 IL4 IL13
32 11.2 IL13 IL4 IL5 TNF
33 11.06 TNF IL5 IL4 IL17A IL13 CXCL8
34 11.04 TNF LAMA3 CXCL8
35 10.97 TNF IL5 IL4 IL13 DSP CXCL8
36 10.79 IL5 IL4 IL13
37 10.6 TNF LAMA3 ITGB4 ITGA6 IL5 IL4
38
Show member pathways
10.36 TNF CXCL8

GO Terms for Pemphigoid

Cellular components related to Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 10.07 PPL PLEC EVPL DST DSP
2 basement membrane GO:0005604 10.01 LAMA3 ITGB4 DST COL17A1
3 cornified envelope GO:0001533 9.96 DSG1 DSG3 DSP EVPL PPL
4 desmosome GO:0030057 9.85 PPL EVPL DSP DSG3 DSG1
5 cellular anatomical entity GO:0110165 9.8 PPL PLEC LAMA3 EVPL DST DSP
6 anchoring junction GO:0070161 9.61 PPL PLEC ITGB4 EVPL DST DSP
7 hemidesmosome GO:0030056 9.32 PLEC LAMA3 ITGB4 DST COL17A1

Biological processes related to Pemphigoid according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.29 TNF IL5 IL17A IL13 CXCL8 CCL11
2 cell adhesion GO:0007155 10.1 CCL11 DSG1 DSG3 DST ITGA6 ITGB4
3 integrin-mediated signaling pathway GO:0007229 10.08 LAMA3 ITGB4 ITGA6 DST
4 epidermis development GO:0008544 10.06 LAMA3 EVPL DSP COL17A1
5 cell-cell adhesion GO:0098609 10.02 LAMA3 ITGA6 DSP DSG3 DSG1
6 positive regulation of B cell proliferation GO:0030890 10.01 IL5 IL4 IL13
7 immune response GO:0006955 9.97 CCL11 CXCL8 HLA-DQB1 IL13 IL17A IL4
8 wound healing GO:0042060 9.96 PPL PLEC EVPL DST DSP
9 cell motility GO:0048870 9.89 DST ITGB4 PLEC
10 nail development GO:0035878 9.85 ITGB4 ITGA6
11 microglial cell activation GO:0001774 9.85 TNF IL4 IL13
12 positive regulation of mononuclear cell migration GO:0071677 9.83 TNF IL4
13 negative regulation of complement-dependent cytotoxicity GO:1903660 9.73 IL4 IL13
14 intermediate filament cytoskeleton organization GO:0045104 9.65 PPL PLEC EVPL DST DSP
15 hemidesmosome assembly GO:0031581 9.32 PLEC LAMA3 ITGB4 DST COL17A1

Molecular functions related to Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.73 PPL PLEC LAMA3 EVPL DST DSP
2 neuregulin binding GO:0038132 9.46 ITGB4 ITGA6
3 cytokine activity GO:0005125 9.4 TNF IL5 IL4 IL17A IL13 CXCL8

Sources for Pemphigoid

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....